Work

Targeting receptor-interacting serine/threonine-protein kinase (RIPK)3 in renal tubulointerstitial fibrosis

Year: 2018
Type: dissertation
Abstract: Chronic kidney disease (CKD) affects almost 10% of the adult population worldwide. Regardless of the initial cause of renal injury, renal fibrosis is the final common pathway of all forms of CKD, including diabetic kidney disease (DKD). However, current therapies to attenuate the development of progressive renal fibrosis are limited to blockade of the renin-angiotensin-aldosterone system (RAAS), achievement of blood pressure targets and in the case of DKD, blood glucose control. More recently inhibition of sodium-glucose linked transporter-2 has shown impressive renoprotective benefits in secondary analyses of major cardiovascular end-point trials. However, studies, where renal disease is a primary endpoint, are awaited. Given the personal and societal impacts of the increasing burden of CKD, it is of utmost importance to identify novel interventions for preventing the progressive renal fibrosis and thus progressive CKD. Receptor-interacting serine/threonine-protein kinase (RIPK) 3, known as a necroptotic kinase, is recognised to be involved in various innate immune responses, including necroptosis and activation of the toll-like receptor (TLR) 2 and 4 pathways and the pyrin domain-containing protein (NLRP) 3 inflammasome. However, the role of RIPK3 in the development of renal cortical fibrosis, and in particular in the pathology observed in the renal tubule under conditions that stimulate a fibrotic response has not been elucidated. In this thesis, mouse models of folic acid (FA)-induced nephropathy (studied at 28 days) and streptozotocin (STZ)-induced diabetic nephropathy (studied at 24 weeks) were developed. RIPK3 knock out (KO) mice were used to determine the therapeutic effect of RIPK3 in renal fibrosis, and the RIPK3 inhibitor dabrafenib was utilized as a pharmacological inhibitor of RIPK3. Human proximal tubular cells exposed to transforming growth factor beta-β1 (TGF-β1) were used as in vitro model to determine the role of necroptosis in the development of tubular pathology under pro-fibrotic influences. Inflammatory and fibrotic markers, as well as the relevant signalling pathways, were examined. Our results show that blockade of RIPK3 genetically or pharmacologically suppressed FA-induced activation of the TLR2 and 4 pathways, the NLRP3 inflammasome and TGF-β1 expression, associated with a reduced myofibroblast activation and interstitial extracellular matrix (ECM) deposition. RIPK3 inhibition also confers renoprotection in the STZ-induced diabetic nephropathy model. A reduction of TGF-β1, NLRP3 activation and TLR4 but not TLR2 was observed in RIPK3 KO mice. Inhibition of necroptosis also reduced TGF-β1 and ECM secretion in tubular cells exposed to TGF-β1. Collectively, the data shown in the thesis uniquely demonstrate that RIPK3 is involved in the development of renal fibrosis via multiple pathways, including necroptosis, TLR2 and 4 signalling and activation of the NLRP3 inflammasome. Given the two strategies to inhibit RIPK3 converge on inhibition of the TLR4 pathway and the NLRP3 inflammasome activation, we consider these are key pathways to inhibit to confer renoprotection. Dabrafenib, the RIPK3 inhibitor, deserves further exploration for repurposing as a targeted renal therapy.
Author: Ying Shi
Language: English
Subfield: Nephrology
Field: Medicine
Open Access status: green
OpenAlex ID: W2981155489
Cites: 149
Cited by: 1
Related to: 10